Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43003 | 1.00 | SCN10A (0.35) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| SCHEMBL5101793 | 1.00 | SCN10A (0.35) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL9767617 | 0.98 | SCN10A (0.34) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL28902277 | 0.98 | SCN10A (0.34) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL14831325 | 0.98 | SCN10A (0.34) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL9767618 | 0.98 | SCN10A (0.34) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL6280216 | 0.98 | SCN10A (0.34) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| Hydrochloric Acid SCHEMBL9767650 | 0.97 | CYP1A2 (0.34) | SCN10ACYP3A4SLC7A5SCN9ACYP1A2 | |
| Histidine SCHEMBL27646599 | 0.94 | SLC7A5 (0.43) | CYP3A4SLC7A5CYP1A2 | |
| Histidine SCHEMBL5221755 | 0.86 | CYP1A2 (0.47) | CYP3A4SLC7A5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043394-A1 | KIT FOR FORMING SUPRAMOLECULAR SELF-ASSEMBLY COMPLEX AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2025-03-06 | — | — | WO | claimed |
| WO-2025048497-A1 | NOVEL HISTIDINE AMIDE CHOLESTEROL COMPOUND, AND RNA DELIVERY LIPID NANOPARTICLES COMPRISING SAME | 충남대학교산학협력단 | 2025-03-06 | — | — | WO | claimed |
| EP-4415561-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-08-21 | — | — | EP | claimed |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2024-01-25 | — | — | US | claimed |
| WO-2023062110-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2023-04-20 | — | — | WO | claimed |
| US-20220315797-A1 | COMBINED USE OF POLYOL ESTERS AND CATIONIC POLYELECTROLYTES IN AQUEOUS POLYURETHANE DISPERSIONS | EVONIK OPERATIONS GMBH (DE) | 2022-10-06 | — | — | US | claimed |
| US-20220259429-A1 | COMBINED USE OF POLYOL ETHERS AND CATIONIC POLYELECTROLYTES IN AQUEOUS POLYURETHANE DISPERSIONS | EVONIK OPERATIONS GMBH (DE) | 2022-08-18 | — | — | US | claimed |
| EP-3999224-A1 | COMBINED USE OF POLYOL ETHERS AND CATIONIC POLYELECTROLYTES IN AQUEOUS POLYURETHANE DISPERSIONS | Evonik Operations GmbH (DE) | 2022-05-25 | — | — | EP | claimed |
| EP-3999602-A1 | COMBINED USE OF POLYOL ESTERS AND CATIONIC POLYELECTROLYTES IN AQUEOUS POLYURETHANE DISPERSIONS | Evonik Operations GmbH (DE) | 2022-05-25 | — | — | EP | claimed |
| WO-2021216529-A1 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2021-10-28 | — | — | WO | claimed |
| EP-1833832-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC Biotech AG (DE) | 2007-09-19 | — | — | EP | claimed |
| WO-2007060028-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | WO | claimed |
| US-6949658-B2 | Process for producing optically active α-amino acid and optically active α-amino acid amide | MITSUBISHI RAYON CO., LTD. (JP) | 2005-09-27 | — | — | US | claimed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-5486595-A | Tumor necrosis factor inhibitors | CENTECOR, INC. (US) | 1996-01-23 | — | — | US | claimed |
| WO-1995026744-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CENTOCOR, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| EP-0371543-A2 | Gastrin releasing peptide antagonists | MERCK & CO. INC. (US) | 1990-06-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, FGB, SARS1 | SCN10A 2292/4885CYP3A4 4383/4885SLC7A5 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.